Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Infect Drug Resist. 2008;1:27-44. Epub 2008 Sep 9.

Current and novel antibiotics against resistant Gram-positive bacteria.

Author information

  • 1Division of Infectious Diseases and HIV Medicine, University Hospitals Case Medical Center, Cleveland OH, USA;

Abstract

The challenge posed by resistance among Gram-positive bacteria, epitomized by methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE) and vancomycin-intermediate and -resistant S. aureus (VISA and VRSA) is being met by a new generation of antimicrobials. This review focuses on the new β-lactams with activity against MRSA (ceftobiprole and ceftaroline) and on the new glycopeptides (oritavancin, dalbavancin, and telavancin). It will also consider the role of vancomycin in an era of existing alternatives such as linezolid, daptomycin and tigecycline. Finally, compounds in early development are described, such as iclaprim, friulimicin, and retapamulin, among others.

KEYWORDS:

Gram-positive bacteria; anti-MRSA cephalosporins; daptomycin; linezolid; lipoglycopeptides; tigecycline; vancomycin

PMID:
21694878
[PubMed]
PMCID:
PMC3108725
Free PMC Article

Images from this publication.See all images (1)Free text

Figure 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk